Entero Therapeutics Files S-1 for Public Offering
Ticker: GRDX · Form: S-1 · Filed: May 12, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | S-1 |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: ipo, registration-statement, pharmaceutical
TL;DR
Entero Therapeutics (formerly First Wave BioPharma) just filed an S-1, looks like they're prepping for a stock offering.
AI Summary
Entero Therapeutics, Inc. filed an S-1 registration statement on May 12, 2025, to register securities for public offering. The company, formerly known as First Wave BioPharma, Inc., is incorporated in Delaware and headquartered in Boca Raton, Florida. This filing indicates a move towards raising capital through the sale of stock.
Why It Matters
This S-1 filing signals Entero Therapeutics' intention to raise capital by selling its securities to the public, which could impact its future growth and stock valuation.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with new public offerings, which inherently carry risks related to market reception and company execution.
Key Numbers
- 333-287185 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 21 — Public Document Count (Indicates the number of documents included in this filing.)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- May 12, 2025 (date) — Filing Date
- First Wave BioPharma, Inc. (company) — Former Company Name
- Richard Paolone (person) — Interim Chief Executive Officer
- Boca Raton, Florida (location) — Principal Executive Offices
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
What was Entero Therapeutics, Inc. previously known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc., and prior to that, AzurRx BioPharma, Inc. and BioPharma d'Azur, Inc.
Who is the Interim Chief Executive Officer of Entero Therapeutics, Inc.?
Richard Paolone is the Interim Chief Executive Officer.
Where are Entero Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida 33431.
When was the company incorporated?
The company was incorporated in Delaware.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on May 12, 2025 by Richard Paolone regarding Entero Therapeutics, Inc. (GRDX).